suppress VSMC proliferation, 16 promote endothelial repair, 17 and enhance endothelial function. 18 These cardioprotective properties of HDLs suggest that therapies that increase endogenous HDL-C levels may attenuate in-stent restenosis. Additional © 2017 American Heart Association, Inc.
A ngioplasty and stent deployment, the most common procedures for treating atherosclerotic lesions, have a significant failure rate because of restenosis of the culprit artery. 1 Current restenosis rates with bare metal stents are 10% to 30%. 2 Although the rate of restenosis is lower with drug-eluting stents (≈3.5% after 1 year 3 ), their use requires 12 months of dual antiplatelet therapy to reduce the risk of stent-induced thrombosis. This is associated with long-term safety concerns, especially neoatherosclerosis and fracture-related adverse pathological events. 4, 5 This complicates management of patients who require further procedures during the first year after stent deployment. Restenosis rates for bare metal and drug-eluting stents are also increased in people with diabetes mellitus. 2 There is thus an unmet need for therapeutic interventions that prevent stentinduced restenosis. The pathogenesis of in-stent restenosis is multifactorial, with endothelial dysfunction, 6 inflammatory cell accumulation in blood vessels, 7 intimal vascular smooth muscle (VSMC) proliferation, 8 thrombus formation, 9 deposition of extracellular matrix, 10 and oxidative modification of proteins, 11 all contributing to neointimal formation. Plasma high-density lipoprotein cholesterol (HDL-C) levels correlate inversely with the risk of having a cardiovascular event. 12 HDLs have several potentially cardioprotective properties, the best known of which relates to cholesterol removal from macrophages in the artery wall in the first step of reverse cholesterol transport. 13, 14 HDLs also inhibit vascular inflammation, evidence that high HDL levels protect against in-stent restenosis comes from peripheral artery disease and diabetes mellitus studies, where patients with in-stent restenosis have lower plasma HDL-C levels than those without in-stent restenosis. 19, 20 A low HDL cholesterol efflux capacity at baseline also predicts increased coronary restenosis risk in patients with stable angina and stent implantation 21 while treatment with reconstituted HDLs inhibits in-stent stenosis in porcine coronary arteries. 22 CETP (cholesteryl ester transfer protein) transfers cholesteryl esters from HDLs to low-density lipoproteins and triglyceride-rich lipoproteins. 23 Inhibition of CETP activity increases HDL-C and apoA-I (apolipoprotein A-I) levels and decreases non-HDL cholesterol levels. We have reported that increasing HDL-C levels with the CETP inhibitor des-fluoro-anacetrapib enhances endothelial repair, improves endothelial function, inhibits VSMC proliferation, and reduces intimal hyperplasia in New Zealand White (NZW) rabbits with endothelial denudation of the abdominal aorta. 24 The peroxisome proliferator-activated receptor-α agonist, fenofibrate, also inhibits CETP activity and reduces intimal hyperplasia after coronary stenting. 25 In this study, stent-induced neointimal hyperplasia was assessed in des-fluoro-anacetrapib-treated NZW rabbits with endothelial denudation of the iliac artery and stent deployment. Des-fluoro-anacetrapib is an active analog of anacetrapib with 1 less fluorine atom than the parent compound. 24 Treatment with des-fluoro-anacetrapib increased plasma HDL-C and apoA-I levels and inhibited stent-induced VSMC proliferation and neointimal hyperplasia in these animals by a mechanism that was dependent on scavenger receptor class B type 1 (SR-B1), the adaptor PDZK1 (PDZ domain-containing protein 1), and activation of the phosphatidylinositol-3-kinase (PI3K)/Akt signal transduction pathway.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Treatment With Des-Fluoro-Anacetrapib Increases HDL-C and ApoA-I Levels in NZW Rabbits
Dietary supplementation with 0.14% (wt/wt) des-fluoroanacetrapib reduced CETP activity by 85±9.8% in NZW rabbits relative to control, chow-fed animals ( Figure IA in the online-only Data Supplement; P<0.001). CETP inhibition increased plasma apoA-I levels from 0.54±0.03 mg/mL for the control animals to 0.83±0.04 mg/mL for the des-fluoroanacetrapib-treated animals ( Figure IB in the online-only Data Supplement; P<0.001). Plasma HDL-C levels increased from 0.37±0.03 mmol/L in the control animals to 0.82±0.07 mmol/L in the des-fluoro-anacetrapib-treated animals ( Figure  IC in the online-only Data Supplement; P<0.001). Resolution of plasma lipoproteins by gel permeation chromatography confirmed the increase in HDL-C levels. HDLs from the desfluoro-anacetrapib-treated animals eluted earlier than HDLs from the control animals, which is consistent with an increase in HDL particle size Figure ID in the online-only Data Supplement). Treatment with des-fluoro-anacetrapib did not affect non-HDL-C levels ( Figure ID in the online-only Data Supplement), and plasma triglyceride levels were unchanged (2.01±0.34 mmol/L for control versus 1.56±0.36 mmol/L for des-fluoro-anacetrapib-treated animals).
Treatment With Des-Fluoro-Anacetrapib Inhibits Neointimal Hyperplasia in NZW Rabbits With Balloon Injury and Stent Deployment in the Iliac Artery
We have previously reported that des-fluoro-anacetrapib treatment of NZW rabbits with balloon injury of the abdominal aorta inhibits intimal hyperplasia and increases VSMC proliferation. 24 In the present study, endothelial denudation of the iliac artery and bare metal stent deployment induced neointimal formation ( Figure 1 ) and VSMC proliferation in the control animals ( Figure II in the online-only Data Supplement). The neointimal area in the stented iliac arteries of the desfluoro-anacetrapib-treated rabbits was decreased by 43±5.6% relative to control animals ( Figure 1A and 1B; P<0.001) while the media area was unaffected ( Figure 1A and 1C) . Desfluoro-anacetrapib treatment decreased the intima/media ratio of the stented iliac arteries by 46±4.2% ( Figure 2D ) while the lumen area increased by 12±2.4% ( Figure 1E ; P<0.001 and P<0.05 compared with control, respectively). Treatment with des-fluoro-anacetrapib also inhibited VSMC proliferation in the stented iliac arteries ( Figure IIA 
HDLs From Des-Fluoro-AnacetrapibTreated NZW Rabbits Inhibit HASMC Proliferation and Migration
To determine whether the decreased VSMC proliferation in des-fluoro-anacetrapib-treated NZW rabbits was because of improved HDL function, or due to increase in plasma HDL levels, HDLs were isolated from the control-and des-fluoroanacetrapib-treated animals and incubated with human aortic smooth muscle cells (HASMCs) at equivalent apoA-I concentrations and at apoA-I concentrations that replicated their ontreatment plasma levels at the time of euthanasia.
Incubation of HASMCs with PBS or isolated HDLs from control animals (Ctrl) at an apoA-I concentration comparable to that in plasma (0.54 mg/mL) did not affect cell proliferation High-density lipoproteins (HDLs) from des-fluoroanacetrapib (dfAna)-treated New Zealand White (NZW) rabbits decrease human aortic smooth muscle cell (HASMC) proliferation and migration. HDLs were isolated from plasma of control and dfAna-treated NZW rabbits after endothelial denudation of the iliac artery and bare metal steel deployment as described in the legend to Figure 1 . HASMCs were incubated for 24 h with PBS or isolated HDLs at final apolipoprotein A-I (apoA-I) concentrations comparable to their plasma levels: 0.54 mg/mL for control (Ctrl) and 0.83 mg/mL for 0.14% dfAna-treated rabbits. A, HASMC proliferation. B, HASMC proliferation assessed as %BrdU (5-bromo-2'-deoxyuridine)-positive cells. C, HASMC migration was quantified as the number of cells that migrated past the wound edge (black line). HASMC proliferation (D) and migration (E) after incubation for 24 h with isolated HDLs from control (Ctrl) and dfAna-treated rabbits at a final apoA-I concentration of 0.5 mg/mL. Data are expressed as mean±SEM, n=6 to 7, #P<0.05, ##P<0.01, ###P<0.001. hpf indicates high power field.
of HASMCs with HDLs from des-fluoro-anacetrapib-treated rabbits reduced the number of cells that migrated across the wound by 34±13% relative to HDLs from control rabbits ( Figure 2C , closed bars; P<0.05). Incubation of HASMCs with HDLs from control and des-fluoro-anacetrapib-treated rabbits at equivalent apoA-I concentrations did not affect cell proliferation ( Figure 2D ) or migration ( Figure 2E ). Taken together, these results indicate that des-fluoro-anacetrapib treatment inhibits VSMC proliferation in balloon-injured, stented NZW rabbit iliac arteries by increasing plasma HDL levels, not by increasing HDL function.
HDLs From Des-Fluoro-Anacetrapib-Treated NZW Rabbits Inhibit HASMC Proliferation and Migration in an SR-B1-, PDZK1-, and PI3K/Akt-Dependent Manner
As HDLs have been reported to inhibit smooth muscle cell proliferation 16 and migration 26 in an SR-B1/PDZK1-and PI3K/Akt-dependent manner, 27, 28 we next asked whether this was also the case for HDLs from des-fluoro-anacetrapibtreated rabbits.
Transfection of HASMCs with SR-B1 siRNA (small interfering RNA) or PDZK1 siRNA decreased SR-B1 ( Figure 3A ) and PDZK1 ( Figure 3B ) protein levels by 67±5.6% and 56±3.8%, respectively, compared with HASMCs transfected with scrambled siRNA (siControl; P<0.01 for both). The transfected cells were then incubated in the absence or presence of HDLs from rabbits treated with des-fluoro-anacetrapib at an apoA-I concentration identical to that in plasma at the time of euthanasia (0.83 mg/mL). Incubation of nontransfected HASMCs and cells transfected with scrambled siRNA in the presence of PBS did not affect cell proliferation ( Figure 3C ) or migration ( Figure 3D ). There was a trend toward decreased cell proliferation ( Figure 3E and 3G, closed bars) and migration ( Figure 3F and 3H, closed bars) in HASMCs transfected with SR-B1 siRNA or PDZK1 siRNA, but this did not reach statistical significance. Incubation of scrambled siRNA-transfected HASMCs (siControl) with HDLs from des-fluoro-anacetrapib-treated rabbits decreased cell proliferation by 29±3.2% ( Figure 3E , open bars) and 43±8.4% ( Figure 3G , open bars) while cell migration decreased by 44±7.1% ( Figure 3F , open bars) and 48±4.6% ( Figure 3H , open bars; P<0.01 for all).
Transfection of HASMCs with Akt siRNA decreased Akt protein levels by 73±1.1% compared with cells transfected with scrambled siRNA (siControl; Figure 4A des-fluoro-anacetrapib-treated rabbits abolished the reduction in proliferation ( Figure 4D , closed bars) and migration ( Figure 4E, closed bars) .
To determine whether the HDL-mediated inhibition of HASMC proliferation and migration was dependent on the ATP-binding cassette transporters ABCA1 and ABCG1, cells were transfected with ABCA1 siRNA, ABCG1 siRNA, or scrambled siRNA (siControl). Transfection with ABCA1 and ABCG1 siRNA decreased ABCA1 ( Figure IIIA 
HDLs From Des-Fluoro-AnacetrapibTreated NZW Rabbits Protect Against TNF-α-Induced HASMCs Proliferation
Progression of neointimal hyperplasia after balloon angioplasty and stent placement has been attributed to vascular inflammation. 29 We have also reported that HDLs from normal human plasma protect against proinflammatory cytokineinduced VSMC proliferation in vitro. 16 To determine whether this is also the case for HDLs from des-fluoro-anacetrapibtreated NZW rabbits, HASMCs were pre-incubated with HDLs from control and des-fluoro-anacetrapib-treated rabbits at apoA-I concentrations that replicated their on-treatment plasma levels at euthanasia. The HASMCs were then incubated in the presence and absence of tumor necrosis factor-α (TNF-α). Relative to cells incubated in the absence of TNF-α ( Figure 5A , open bar), incubation with TNF-α increased HASMC proliferation by 54±14% ( Figure 5A ; P<0.05). HDLs from the control-and des-fluoro-anacetrapib-treated animals decreased TNF-α-induced HASMC proliferation by 42±4.0% and 53±2.3%, respectively ( Figure 5A ; P<0.001 versus TNF-α only; P<0.05 HDL for control versus treated rabbits).
To determine whether the reduction in TNF-α-induced HASMC proliferation was dependent on SR-B1, the incubations were repeated in HASMCs transfected with scrambled siRNA (siControl) or SR-B1 siRNA. Incubation of the cells transfected with SR-B1 siRNA in the absence of HDLs did not affect TNF-α-induced cell proliferation ( Figure 5B) . Incubation of scrambled siRNA-transfected HASMCs with HDLs from des-fluoro-anacetrapib-treated rabbits decreased 
Treatment With Des-Fluoro-Anacetrapib Inhibits Vascular Inflammation in NZW Rabbits With Balloon Injury and Stent Deployment in the Iliac Artery
Because extravasation of inflammatory cells into the artery wall contributes to progression of neointimal hyperplasia after balloon angioplasty and stent deployment, 29 we asked whether des-fluoro-anacetrapib treatment can also inhibit inflammatory cell accumulation in balloon-injured and stented iliac arteries. NZW rabbits received regular chow or chow supplemented with 0.14% (wt/wt) des-fluoro-anacetrapib for 2 weeks before balloon injury and stent deployment. The animals were euthanized 24 hours poststent deployment.
Relative to control, plasma CETP activity in the desfluoro-anacetrapib-treated rabbits decreased by 90±17% ( Figure 6A ; P<0.01) and plasma apoA-I and HDL-C levels increased by 51±17% (Figure 6B ; P<0.05) and 75±24% ( Figure 6C; P<0.05) , respectively. The number of CD18+ cells in the vessel wall was reduced by 85±9.8% in the des-fluoroanacetrapib-treated animals relative to control ( Figure 6D ; P<0.001). This indicates that des-fluoro-anacetrapib treatment inhibits acute vascular inflammatory responses after balloon injury and stent deployment in the iliac artery of NZW rabbits.
Discussion
The effects of inhibiting CETP with the anacetrapib analogue, des-fluoro-anacetrapib that were observed in this study are most likely a consequence of increased HDL levels rather than changes in non-HDL levels, that were minimal. This study thus supports the notion that increasing HDL-C levels by inhibiting CETP activity with des-fluoro-anacetrapib prevents intimal hyperplasia and inhibits VSMC proliferation in NZW rabbits with balloon injury of the iliac artery and stent deployment. We further demonstrate that HDLs isolated from these animals decrease HASMC proliferation and migration in vitro in an SR-B1/PDZK1-and PI3K/Akt-dependent manner, protect against inflammatory cytokine-induced HASMC proliferation, and inhibit acute vascular inflammatory responses. Because the amino acid sequence of rabbit SR-BI and its human homologue, CLA-1, are 86% homologous, and the proteins are functionally comparable, 30 it is highly likely that the results from the in vitro HASMC experiments also reflect what occurs in smooth muscle cells in the NZW rabbit.
Restenosis is a common problem after stent implantation in humans. Although drug-eluting stents have a lower restenosis rate than bare metal stents, they are associated with a higher rate of cardiac death and myocardial infarction because of stent thrombosis. 31 Even though use of new generation of drug-eluting stents and long-term dual antiplatelet therapy reduces stent thrombosis, neoatherosclerosis is increasingly being recognized as a significant problem. 31 CETP inhibition produces large, cholesteryl esterenriched HDL particles and increases plasma HDL levels in rabbits and humans. 32, 33 CETP inhibition also inhibits atherosclerotic lesion development in rabbits, [33] [34] [35] and anacetrapib reduced major cardiovascular events in the recent REVEAL trial (Randomized EValuation of the Effects of Anacetrapib through Lipid modification). 36 Cardiovascular events were, by contrast, not reduced in earlier clinical outcome trials with other CETP inhibitors. [37] [38] [39] The present study indicates that increasing HDL levels by inhibiting CETP activity with anacetrapib may reduce stentinduced thrombosis and neoatherosclerosis. Because the current results were obtained in normocholesterolemic rabbits, additional investigations in cholesterol-fed animals are warranted. Our results are, however, in line with a significant reduction in revascularization in anacetrapib-treated subjects in the REVEAL trial. 36 We have further established that the reduced neointimal hyperplasia in des-fluoro-anacetrapibtreated rabbits can be attributed directly to the increase in plasma HDL levels, rather than to an improvement in HDL function for a given concentration of apoA-I. This provides clear evidence that CETP inhibition does not generate dysfunctional HDLs, at least in terms of their ability to reduce stent-induced neointimal hyperplasia. It will be of interest to Consistent with previous reports, the present study establishes that HDLs from des-fluoro-anacetrapib-treated NZW rabbits inhibit smooth muscle cell proliferation and migration in an SR-B1-, PDZK1-, and PI3K/Akt-dependent manner. 16, [26] [27] [28] This is in line with evidence that several of the cardioprotective and antidiabetic effects of HDLs are SR-B1 dependent. For example, HDL-induced endothelial nitric oxide synthase activation, 40 the promotion of endothelial cell migration and re-endothelialization after endothelial injury, 27 and increased glucose uptake by adipocytes and glycogen synthesis in muscle 41 are all SR-B1 dependent. Similarly, activation of downstream SR-B1 signaling pathways in endothelial cells is dependent on binding of the C-terminal domain of SR-B1 to PDZK1. Our findings suggest that this is also true for HASMCs. However, a recent study has found that PDZK1 can also protect against neointima formation in ligated carotid arteries in an SR-B1-independent manner. 42 Whether this is also the case for the inhibition of stent-induced neointimal hyperplasia remains to be determined. Stent implantation is associated with acute and chronic inflammation in the vessel wall, both of which have the capacity to contribute to neointimal proliferation. 29 This is driven, at least in part, by recruitment of inflammatory cells to the endothelium and their subsequent migration into the vessel wall. In this study, des-fluoro-anacetrapib treatment inhibited these events in NZW rabbits with balloon injury and stent deployment in the iliac artery, with evidence that the benefit is attributable to the anti-inflammatory properties of HDLs.
In conclusion, this study establishes that increasing circulating HDL levels by inhibiting CETP activity with desfluoro-anacetrapib protects against neointimal hyperplasia in balloon-injured NZW rabbits with stent deployment secondary to inhibition of VSMC proliferation, migration, and inflammation. It remains to be seen whether these mechanisms are also responsible for reduced revascularization rates in people treated with a CETP inhibitor. . Des-fluoro-anacetrapib (dfAna) treatment inhibits inflammatory cell infiltration in New Zealand White (NZW) rabbits with endothelial denudation and stent deployment of the iliac artery. NZW rabbits (n=5/group) received regular chow (control) or chow supplemented with 0.14% (wt/wt) dfAna for 2 wk before iliac artery endothelial denudation and stent deployment. The animals were euthanized 24 h poststent deployment. The stented arteries were resected, fixed in 4% (v/v) cold paraformaldehyde, and sectioned longitudinally before stent removal. A, plasma CETP (cholesteryl ester transfer protein) activity. B, Plasma apolipoprotein A-I (apoA-I) levels. C, Plasma high-density lipoprotein cholesterol (HDL-C) levels. D, Representative cross-sections of arteries immunostained for CD18 (bar=500 µm). Data are expressed as mean±SEM, n=5, *P<0.05, **P<0.01, ***P<0.001 vs control.
